secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-06-09T11:00:23+00:00
Accession:  0001493152-26-027837
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin
--------------------------------------------------------------------------------

- James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).
- Sam Lee remains President and Chief Scientific Officer; James Martin remains CFO.
- Sapirstein receives $265,000 base salary, 50% target bonus, and initial option grant of 235,000 shares at $1.05 vesting over 4 years.
- Additional 235,000 options may be granted on 6-month anniversary subject to performance and board approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer